Scarica l'app Stockscreener
0.9851
1.30%
-0.013
Pre-mercato:
.93
-0.0551
-5.60%
Precedente Chiudi:
$0.9981
Aprire:
$0.99
Volume 24 ore:
53,455
Relative Volume:
0.42
Capitalizzazione di mercato:
$3.18M
Reddito:
-
Utile/perdita netta:
$-736.70K
Rapporto P/E:
-98.51
EPS:
-0.01
Flusso di cassa netto:
$-4.14M
1 W Prestazione:
-22.43%
1M Prestazione:
-9.62%
6M Prestazione:
-43.38%
1 anno Prestazione:
-56.60%
Intervallo 1D:
$0.96
$1.005
Intervallo di 1 settimana:
$0.85
$1.29
Portata 52W:
$0.85
$7.00
Xortx Therapeutics Inc Stock (XRTX) Company Profile
Nome
Xortx Therapeutics Inc
Settore
Industria
Telefono
-
Indirizzo
-
Confronta XRTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XRTX
Xortx Therapeutics Inc
|
0.9851 | 3.18M | 0 | -736.70K | -4.14M | -0.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Xortx Therapeutics Inc Borsa (XRTX) Ultime notizie
XORTX Therapeutics Appoints New Auditor to Enhance Financial Oversight - TipRanks
XORTX Therapeutics Announces Auditor Transition - MSN
XORTX Announces Change of Auditor - GlobeNewswire
XORTX Therapeutics Announces Auditor Change to Davidson & Company LLP - StockTitan
XORTX Therapeutics Expands Pipeline with Late-Stage Gout Program - TipRanks
XORTX Adds Late Stage Gout Program to Pipeline - GlobeNewswire
XORTX Launches XRx-026 Program for Allopurinol-Intolerant Gout Patients, Targets FDA Approval - StockTitan
XORTX appoints finance veteran as its new CFO - MSN
XORTX Therapeutics Welcomes New CFO Dr. Bumby - TipRanks
XORTX Strengthens Executive Team - The Manila Times
XORTX Therapeutics Taps Former Eli Lilly Veteran Dr. Michael Bumby as New CFO - StockTitan
XORTX Therapeutics Unveils New Kidney Disease Discoveries - TipRanks
XORTX Announces Presentation at the Rare and Genetic Disease Summit - GlobeNewswire
XORTX Therapeutics Unveils Breakthrough ADPKD Research: Genetic Factors Key to Disease Progression - StockTitan
XORTX Therapeutics Inc. Faces Financial Challenges - TipRanks
XORTX Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2024 - sharewise
XORTX Highlights Kidney Disease Study at ASN - TipRanks
XORTX Secures $1.5 Million in Latest Offering - TipRanks
XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewswire
XORTX Therapeutics stock falls after pricing $1.5M capital raise - MSN
XORTX Therapeutics Announces $1.5 Million Offering - TipRanks
XORTX Announces Pricing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewswire
The Significance of Moving Averages in XORTX Therapeutics Inc Inc. (XRTX) Price Performance - The InvestChronicle
XORTX Therapeutics Advances Precision Kidney Care - TipRanks
XORTX Initiates Precision Medicine Program - GlobeNewswire
XORTX Therapeutics Inc. Initiates Precision Medicine Program - Marketscreener.com
S&P 500 Financials [Sector] (SRFI) QuotePress Release - The Globe and Mail
TSX 60 Shariah Index (TXSI) QuotePress Release - The Globe and Mail
XORTX Therapeutics (NASDAQ:XRTX) Stock Quotes, Forecast and News Summary - Benzinga
SEC Form 424B3 filed by XORTX Therapeutics Inc. - Quantisnow
Form 424B3 XORTX Therapeutics Inc. - StreetInsider.com
XORTX Therapeutics Shareholders Approve Key Decisions - TipRanks
XORTX Announces Results of Annual and Special Meeting of Shareholders - GlobeNewswire
XORTX Announces Results of Annual and Special Meeting of Shareholders | XRTX Stock News - StockTitan
Tesla Inc (TSLA-Q) QuotePress Release - The Globe and Mail
XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A - GlobeNewswire
S&P 500 Index (INX) QuotePress Release - The Globe and Mail
Ford Motor Company (F-N) QuotePress Release - The Globe and Mail
S&P 500 Communication Services [Sector] (SRTS) QuotePress Release - The Globe and Mail
Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail
XORTX Prepares for Shareholders’ Vote on Key Resolutions - TipRanks
XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of Shareholders - GlobeNewswire
Xortx Therapeutics Inc Azioni (XRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):